NCT07368985 2026-01-27Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix CancerErasmus Medical CenterPhase 2 Not yet recruiting87 enrolled
NCT07218003 2025-10-24A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4Rondo TherapeuticsPhase 1 Recruiting149 enrolled
NCT04660929 2024-12-18CAR-macrophages for the Treatment of HER2 Overexpressing Solid TumorsCarisma Therapeutics IncPhase 1 Active not recruiting48 enrolled
NCT04230954 2022-06-07Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical CancerUniversity of South AlabamaPhase 2 Terminated5 enrolled